Precision BioSciences Inc. (NASDAQ: DTIL) presented preclinical data showing its PBGENE-DMD gene therapy demonstrated higher efficacy when administered to younger ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA